Skip to main content
Clinical Trials/NCT05885646
NCT05885646RecruitingNot Applicable

Treatment of Epilepsy Syndromes of Childhood With Sleep Activation Using Sulthiame: an Exploratory Study of the Short Term Effect on EEG

University Hospital, Angers3 sites in 1 country15 target enrollmentStarted: October 17, 2023Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
15
Locations
3
Primary Endpoint
Percentage of patients showing improved sleep EEG at day 14 compared to baseline EEG

Study Overview

Brief Summary

The effect of sulthiame on EEG has been studied in epilepsy syndromes of childhood with sleep activation by comparing sleep EEG obtained at baseline and after 4 weeks of treatment. The aim of the study is to know if an effect is still identifiable after 2 weeks of treatment by performing sleep EEG recordings after 2 and 4 weeks of treatment, respectively.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
6 Years to 15 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of epilepsy syndromes of childhood with sleep activation
  • Failure of at least two anti-epileptic drugs (AED)
  • Sleep EEG performed in the last 7 days before inclusion and showing interictal epileptiform discharges (baseline EEG)

Exclusion Criteria

  • Previous trial with sulthiame
  • More than 2 AED at inclusion
  • Use of corticosteroids at inclusion
  • Change in the anti-epileptic treatment in the 7 days before baseline EEG

Outcomes

Primary Outcomes

Percentage of patients showing improved sleep EEG at day 14 compared to baseline EEG

Time Frame: 14 days

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
University Hospital, Angers
Sponsor Class
Other Gov
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials